Advertisement

Journal of Neuro-Oncology

, Volume 87, Issue 1, pp 85–90 | Cite as

A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases

  • Fabio M. Iwamoto
  • Antonio M. Omuro
  • Jeffrey J. Raizer
  • Craig P. Nolan
  • Adília Hormigo
  • Andrew B. Lassman
  • Igor T. Gavrilovic
  • Lauren E. AbreyEmail author
Clinical-Patient Studies

Abstract

Purpose To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors. Methods Patients ≥18 years of age and with Karnofsky performance scale (KPS) ≥ 60, adequate organ function and progressive or recurrent brain metastases were eligible. This was a phase II trial with 28-day cycles using temozolomide (150 mg/m2, days 1–7 and 15–21) and vinorelbine 25 or 30 mg/m2 on days one and eight. The primary endpoint was objective radiographic response. Results Thirty-eight patients (15 men, 23 women) with a median age of 57 years (range, 39–75) and median KPS of 80 were enrolled. The primary tumor sites were lung (n = 20), breast (n = 11), colorectal (n = 2), kidney (n = 2), bladder (n = 1), endometrium (n = 1), head and neck (n = 1). Prior therapies included chemotherapy (97%), whole-brain radiation therapy (79%), brain metastasis resection (53%) and stereotatic radiosurgery (47%). Objective radiographic response rate was 5% (one complete response and one minor response); five patients had stable disease, 29 progressive disease and two patients were not evaluable. Twenty-nine patients (76%) have died and the median follow-up of survivors was six months. Median progression-free and overall survivals were 1.9 and 5 months, respectively. Grade 3/4 toxicities were mainly hematological and two patients discontinued the study due to myelosuppression. Conclusions In this heavily pretreated population of patients with brain metastases, adding vinorelbine and increasing the intensity of temozolomide do not improve response rates compared to previous studies with single-agent temozolomide at standard doses.

Keywords

Brain metastasis Temozolomide Vinorelbine Lung cancer Breast cancer 

Notes

Acknowledgements

LE Abrey has received honoraria and grant support from Schering Plough, Inc. AM Omuro and JJ Raizer have received honoraria from Schering Plough, Inc. This study was supported in part by an unrestricted educational grant from Integrated Therapy Group, Inc. (ITGI), a subsidiary of Schering-Plough Corporation. We thank Judy Lampron for her expert editorial assistance.

References

  1. 1.
    Omuro AM, Abrey LE (2004) Brain metastases. Curr Neurol Neurosci Rep 4:205–210PubMedCrossRefGoogle Scholar
  2. 2.
    Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500PubMedCrossRefGoogle Scholar
  3. 3.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672PubMedCrossRefGoogle Scholar
  4. 4.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  5. 5.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  6. 6.
    Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22:2101–2107PubMedCrossRefGoogle Scholar
  7. 7.
    Raymond E, Izbicka E, Soda H, Gerson SL, Dugan M, Von Hoff DD (1997) Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 3:1769–1774PubMedGoogle Scholar
  8. 8.
    Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY et al (2001) A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53:259–265PubMedCrossRefGoogle Scholar
  9. 9.
    Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P et al (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12:249–254PubMedCrossRefGoogle Scholar
  10. 10.
    Fornier M, Norton L (2005) Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 7:64–69PubMedCrossRefGoogle Scholar
  11. 11.
    Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115PubMedGoogle Scholar
  12. 12.
    Gregory RK, Smith IE (2000) Vinorelbine–a clinical review. Br J Cancer 82:1907–1913PubMedCrossRefGoogle Scholar
  13. 13.
    Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE (2006) Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol 78:277–280PubMedCrossRefGoogle Scholar
  14. 14.
    Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C et al (2003) Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 39:1271–1276PubMedCrossRefGoogle Scholar
  15. 15.
    Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P et al (2005) Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 50:247–254PubMedCrossRefGoogle Scholar
  16. 16.
    Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M et al (2005) Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neurooncol 71:61–65PubMedCrossRefGoogle Scholar
  17. 17.
    Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M et al (2006) Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 57:34–39PubMedCrossRefGoogle Scholar
  18. 18.
    Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G et al (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) protocol 95–1. Ann Oncol 12:59–67PubMedCrossRefGoogle Scholar
  19. 19.
    Bernardo G, Cuzzoni Q, Strada MR, Bernardo A, Brunetti G, Jedrychowska I et al (2002) First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 20:293–302PubMedCrossRefGoogle Scholar
  20. 20.
    Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2007

Authors and Affiliations

  • Fabio M. Iwamoto
    • 1
  • Antonio M. Omuro
    • 1
    • 2
  • Jeffrey J. Raizer
    • 1
    • 3
  • Craig P. Nolan
    • 1
  • Adília Hormigo
    • 1
  • Andrew B. Lassman
    • 1
  • Igor T. Gavrilovic
    • 1
  • Lauren E. Abrey
    • 1
    Email author
  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Service de Neurologie MazarinGroupe Hospitalier Pitié-SalpêtrièreParisFrance
  3. 3.Davee Department of Neurology and Neurological Sciences, Feinberg School of MedicineNorthwestern UniversityChicagoUSA

Personalised recommendations